Agnieszka Jóźwik
YOU?
Author Swipe
View article: Data from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Data from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Background:UCART191 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells.Methods:UCART19 was administered to 25 adult patients with relapsed or refrac…
View article: Supplementary Tables S1-S4 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Tables S1-S4 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Table S1: Representativeness of CALM study participants; Table S2: UCART19 dose and cellular kinetics analysis; Table S3: Characteristics of UCART19 PBMC donors; Table S4: Impact of UCART19 and alemtuzumab doses on UCART19 expansion.
View article: Supplementary Tables S1-S4 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Tables S1-S4 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Table S1: Representativeness of CALM study participants; Table S2: UCART19 dose and cellular kinetics analysis; Table S3: Characteristics of UCART19 PBMC donors; Table S4: Impact of UCART19 and alemtuzumab doses on UCART19 expansion.
View article: Supplementary Figures S1-S9 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Figures S1-S9 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Fig.S1: Schematic diagram of CALM study design; Fig.S2: Correlation of UCART19 transgene levels evaluated by qPCR in paired peripheral blood and bone marrow aspirate samples; Fig.S3 & S4: Impact of demographic characteristics, prior therap…
View article: Data from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Data from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Background:UCART191 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells.Methods:UCART19 was administered to 25 adult patients with relapsed or refrac…
View article: Supplementary Materials & Methods SM1 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Materials & Methods SM1 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Additional information regarding the CALM study (including study population and summary results) and UCART19 product characterization.
View article: Supplementary Materials & Methods SM1 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Materials & Methods SM1 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Additional information regarding the CALM study (including study population and summary results) and UCART19 product characterization.
View article: Supplementary Figures S1-S9 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Supplementary Figures S1-S9 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Fig.S1: Schematic diagram of CALM study design; Fig.S2: Correlation of UCART19 transgene levels evaluated by qPCR in paired peripheral blood and bone marrow aspirate samples; Fig.S3 & S4: Impact of demographic characteristics, prior therap…
View article: Selected Predictors of COVID-19 Mortality in the Hospitalised Patient Population in a Single-Centre Study in Poland
Selected Predictors of COVID-19 Mortality in the Hospitalised Patient Population in a Single-Centre Study in Poland Open
Background: The correct analysis of COVID-19 predictors could substantially improve the clinical decision-making process and enable emergency department patients at higher mortality risk to be identified. Methods: We retrospectively explor…
View article: Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia Open
Background: UCART191 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. Methods: UCART19 was administered to 25 adult patients with relapsed or ref…
View article: Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors Open
Multiple myeloma remains an incurable plasma cell malignancy despite the rapidly evolving treatment landscape. Chimeric antigen receptor T cells targeted against BCMA have recently shown great promise in relapsed refractory multiple myelom…
View article: Innate-like Gene Expression of Lung-Resident Memory CD8<sup>+</sup> T Cells during Experimental Human Influenza: A Clinical Study
Innate-like Gene Expression of Lung-Resident Memory CD8<sup>+</sup> T Cells during Experimental Human Influenza: A Clinical Study Open
Rationale: Suboptimal vaccine immunogenicity and antigenic mismatch, compounded by poor uptake, means that influenza remains a major global disease. T cells recognizing peptides derived from conserved viral proteins could enhance vaccine-i…
View article: Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma Open
CD19-targeted autologous chimeric antigen receptor (CAR) T-cell therapy has shown dramatic response rates in relapsed and refractory patients with B-cell malignancies [1][2][3][4].However, a growing body of literature has demonstrated T-ce…
View article: Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection
Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection Open
ACHOO!-trophils? Why some individuals come down with a cold in any given year, whereas others are spared, is poorly understood. Habibi et al. exposed volunteers to respiratory syncytial virus (RSV), one of the pathogens responsible for the…
View article: Antibody and T cell responses against avian and microbial antigens associate with hypersensitivity pneumonitis disease parameters in pigeon breeders
Antibody and T cell responses against avian and microbial antigens associate with hypersensitivity pneumonitis disease parameters in pigeon breeders Open
Pigeon Fancier's Lung (PFL) is a form of Hypersensitivity Pneumonitis where lung pathology occurs due to an immune reaction to repeated inhalation of large amounts of feather-derived and droppings-derived dust [1]. The 1μm dust particles p…
View article: Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection
Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection Open
BACKGROUNDRespiratory syncytial virus (RSV) is an important cause of acute pulmonary disease and one of the last remaining major infections of childhood for which there is no vaccine. CD4+ T cells play a key role in antiviral immunity, but…
View article: Emerging Cellular Therapies: T Cells and Beyond
Emerging Cellular Therapies: T Cells and Beyond Open
Cellular therapies, including those based on T cells, are becoming approved options for clinicians treating a range of diseases. Cytotoxic T lymphocytes (CTLs) can be modified ex vivo to express receptors such as chimeric antigen receptors…
View article: Allogeneic CAR-T Cells: More than Ease of Access?
Allogeneic CAR-T Cells: More than Ease of Access? Open
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymp…
View article: Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans
Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans Open
Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing significant morbidity and mortality. No vaccine or specific, effective treatment is currently available. A more complete understanding …